Company / Shareholders' Equity
Outlook Therapeutics, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$73.1M
FY2025
5-year range
-$73.1M / -$16.1M
FY2021-FY2025
Trend
-353.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Outlook Therapeutics, Inc. reports negative total equity of -$73M in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$73M in FY2025.
Declined from -$26M to -$73M over the past 6 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, shareholders' equity decreased 353.1% year-over-year.
- Peak shareholders' equity was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -13.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$73.1M | -353.1% |
| FY2020 | -$16.1M | +36.9% |
| FY2019 | -$25.5M | +0.0% |
| FY2018 | -$25.5M | +24.1% |
| FY2017 | -$33.7M | -547.1% |
| FY2016 | -$5.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026